Investigational drug · Phase 2
S243249
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "S243249"
First trial start
2027
Feb 1, 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "S243249", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Acute Leukemia
- Relapsed or Refractory Acute Myeloid Leukemia
Approved drugs for the same conditions: Acute myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "S243249" as an intervention, largest first.
- S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c MutationNot yet recruiting
ServierIndustry
NCT07722312 · 80 participants (planned) · Start Feb 1, 2027 · Primary completion Aug 11, 2029
Drug: S243249 600mg; S243249 400mg and 2 more · For: Relapsed or Refractory Acute Leukemia; Relapsed or Refractory Acute Myeloid Leukemia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.